Mark Heffernan
Directeur Général chez Stonehaven Incubate AG
Profil
Mark Heffernan is the founder of Nexvet Biopharma Plc, Opsona Therapeutics Ltd., and Nexvet Australia Pty Ltd.
Nexvet Biopharma Plc was founded in 2011, Opsona Therapeutics Ltd.
was founded in 2003, and Nexvet Australia Pty Ltd.
was founded in 2010.
He held the titles of Chief Executive Officer & Director at Nexvet Biopharma Plc from 2011 to 2017, Chief Executive Officer & Non-Executive Director at Opsona Therapeutics Ltd.
from 2003 to 2011, and Chief Executive Officer & Director at Nexvet Australia Pty Ltd.
from 2015 to 2017.
Currently, he is the Chief Executive Officer at Stonehaven Incubate AG and a Director at AniV8, Inc. He has previously worked as the Chief Executive Officer at Scout Bio, Inc. and as a Principal at Percheron Therapeutics Ltd.
He received his undergraduate and doctorate degrees from Monash University.
Postes actifs de Mark Heffernan
| Sociétés | Poste | Début |
|---|---|---|
Stonehaven Incubate AG
 Stonehaven Incubate AG Financial ConglomeratesFinance Stonehaven Incubate AG provides investment services in animal health sector. The company is headquartered in Andermatt, Switzerland. | Directeur Général | - |
AniV8, Inc.
 AniV8, Inc. Miscellaneous Commercial ServicesCommercial Services AniV8, Inc. is an American clinical sensor technology company that aims to improve animal health by applying innovative, high-tech sensor science to targeted disease states. AniV8 has developed the first wearable health monitor for dogs and cats that will diagnose and monitor osteoarthritis (OA) pain using proprietary algorithms to measure the quality of movement. The device has clear points of difference from competitors and is the only wearable to measure the quality, not quantity, of motion. AniV8 has completed an oversubscribed pre-seed funding round and has collaborated with Elanco Animal Health to evaluate its wearable technology in research settings. The company was founded by B Duncan X. Lascelles, who is also the director and chief scientific advisor, and the CEO is Ellie Virtue. | Directeur/Membre du Conseil | - |
Anciens postes connus de Mark Heffernan
| Sociétés | Poste | Fin |
|---|---|---|
| NEXVET BIOPHARMA PUBLIC LIMITED CO | Fondateur | 31/07/2017 |
Nexvet Australia Pty Ltd.
 Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Fondateur | 01/07/2017 |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Fondateur | 06/05/2011 |
Scout Bio, Inc.
 Scout Bio, Inc. Pharmaceuticals: MajorHealth Technology Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA. | Directeur Général | - |
| PERCHERON THERAPEUTICS LIMITED | Corporate Officer/Principal | - |
Formation de Mark Heffernan
| Monash University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PERCHERON THERAPEUTICS LIMITED | Health Technology |
| Entreprise privées | 6 |
|---|---|
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Nexvet Australia Pty Ltd.
Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Nexvet Biopharma Plc
 Nexvet Biopharma Plc Pharmaceuticals: MajorHealth Technology Nexvet Biopharma Plc engaged in the provision of integrated biopharmaceutical business. It focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. The company was founded in September 2014 and was headquartered in Dublin, Ireland. | Health Technology |
Scout Bio, Inc.
Scout Bio, Inc. Pharmaceuticals: MajorHealth Technology Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA. | Health Technology |
Stonehaven Incubate AG
Stonehaven Incubate AG Financial ConglomeratesFinance Stonehaven Incubate AG provides investment services in animal health sector. The company is headquartered in Andermatt, Switzerland. | Finance |
AniV8, Inc.
AniV8, Inc. Miscellaneous Commercial ServicesCommercial Services AniV8, Inc. is an American clinical sensor technology company that aims to improve animal health by applying innovative, high-tech sensor science to targeted disease states. AniV8 has developed the first wearable health monitor for dogs and cats that will diagnose and monitor osteoarthritis (OA) pain using proprietary algorithms to measure the quality of movement. The device has clear points of difference from competitors and is the only wearable to measure the quality, not quantity, of motion. AniV8 has completed an oversubscribed pre-seed funding round and has collaborated with Elanco Animal Health to evaluate its wearable technology in research settings. The company was founded by B Duncan X. Lascelles, who is also the director and chief scientific advisor, and the CEO is Ellie Virtue. | Commercial Services |